Company profile: Biotheranostics
1.1 - Company Overview
Company description
- Provider of commercial-stage molecular diagnostics, delivering diagnostic, prognostic, and predictive tests that support physicians in treating cancer, including Breast Cancer Index, a genomic test predicting benefit of extended endocrine therapy in HR+, early-stage breast cancer, and CancerTYPE ID, a gene expression assay identifying tumor type/subtype in metastatic cancer with unknown or unclear diagnoses.
Products and services
- CANCERTYPE ID: A gene expression-based assay that identifies tumor type and subtype in metastatic cancer with unknown or unclear diagnoses, supporting physicians in the treatment of cancer patients
- BREAST CANCER INDEX: A genomic test that predicts the benefit of extended endocrine therapy in HR+, early-stage breast cancer, supporting physicians in the treatment of cancer patients
- Evidence-Based Biomarker Development: Evidence-based, molecular diagnostics programs that develop and deliver diagnostic, prognostic, and predictive tests supporting physicians in cancer treatment, addressing unmet medical needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biotheranostics
Synlogic
HQ: United States
Website
- Description: Provider of synthetic biotic medicines designed to perform metabolic functions to treat diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synlogic company profile →
Biocartis
HQ: Switzerland
Website
- Description: Provider of a diagnostics technology platform for multiplexed detection of bio‑analytes, focused on integrated molecular and immunodiagnostics via a proprietary micro‑technology platform. Products include the Idylla fully automated sample‑to‑result real‑time PCR system for molecular diagnostics from various biological samples, and assays such as APIS ESR1, Idylla BRAF, GeneFusion (research use), ctEGFR, and NRAS‑BRAF‑EGFR S492R.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocartis company profile →
Molecular Assemblies
HQ: United States
Website
- Description: Provider of proprietary Fully Enzymatic Synthesis (FES) technology to produce long, pure, accurate DNA up to 400 nucleotides without post-synthesis purification; custom DNA oligos for CRISPR, cloning and NGS; gene editing, protein engineering and gene assembly services; and a partnering program licensing FES for on-site synthesis with an automated platform, proprietary reagents and research-use licenses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Assemblies company profile →
Immuneering
HQ: United States
Website
- Description: Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immuneering company profile →
Cergentis
HQ: The Netherlands
Website
- Description: Provider of services and kits based on proprietary Targeted Locus Amplification (TLA) technology, enabling cost-effective complete sequencing of relevant genes and genomic loci and providing genetic characterization and quality control (QC) to support the development of advanced, safe and effective therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cergentis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biotheranostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biotheranostics
2.2 - Growth funds investing in similar companies to Biotheranostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biotheranostics
4.2 - Public trading comparable groups for Biotheranostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →